Skip to main content
. 2009 Aug;157(8):1541–1548. doi: 10.1111/j.1476-5381.2009.00327.x

Figure 1.

Figure 1

Evaluation of panitumumab immunoreactivity in a competition radioimmunoassay. The immunoreactivity of panitumumab-CHX-A″-DTPA (diethylenetriamine-pentaacetic acid) for purified epidermal growth factor receptor was compared with that of unmodified panitumumab. The anti-CD33 monoclonal antibody, HuM195 was used as a non-specific control.